ZK International Gr Co Bolsa (NASDAQ: ZKIN)

Últimas noticias sobre ZK International Gr Co (NASDAQ:ZKIN) Bolsa

ZK International Gr Co

ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

ZK International Group Co., Ltd - Ordinary Share

ZK International Group Co Ltd

Barclays analyst David Anderson maintains Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) with a Equal-Weight and raises the price target from $145 to $165.

News

Price Target

Analyst Ratings

GTLS

Barclays Maintains Equal-Weight on Chart Industries, Raises Price Target to $165

OLB Group Expands Fintech Offerings With New PayFac Service To Empower Small Business Growth

MASS

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times

Barclays analyst Blayne Curtis maintains TXNM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) with a Overweight and raises the price target from $49 to $56.

TXNM

Barclays Maintains Overweight on TXNM Energy, Raises Price Target to $56

Additionally, divestiture streamlines operations, reducing headcount by approximately 33% and eliminating $20 million in annual operating losses.

Guidance

908 Devices Now Expects To Achieve Adjusted EBITDA Positivity By Q4 2025 And Cash Flow Positivity In 2026

This significant milestone demonstrates the U.S. government's long-standing support of quantum computing and networking
IonQ once again demonstrates its ability to deliver innovative quantum computing and networking systems to customers and partners worldwide

EXTR

Extreme Networks Becomes Official Wi-Fi And Analytics Provider For USL, Transforming Soccer Stadium Connectivity

Nordstrom, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/JWN/earnings">closing bell, on Tuesday, March 4</a>.
Analysts expect the Seattle, Washington-based company to report quarterly earnings at 93 cents per share, down from 96 cents per share in the year-ago period. Ross Stores projects quarterly revenue of $4.33 billion, compared to $4.42 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 26, Nordstrom reported that its board of directors approved a quarterly dividend of 19 cents per share.
Nordstrom shares fell 0.2% to close at $24.24 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/JWN/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Evercore ISI Group analyst Michael Binetti maintained an In-Line rating and raised the price target from $22 to $24 on Jan. 13, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Jay Sole upgraded the stock from Sell to Neutral and increased the price target from $14.5 to $24 on Jan. 10, 2025. This analyst has an accuracy rate of 70%.</li>
<li>B of A Securities analyst Lorraine Hutchinson maintained an Underperform rating and raised the price target from $20 to $22 on Nov. 27, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Citigroup analyst Paul Lejuez maintained a Neutral rating and increased the price target from $22 to $23 on Nov. 19, 2024. This analyst has an accuracy rate of 65%.</li>
<li>JP Morgan analyst Matthew Boss maintained an Underweight rating and increased the price target from $19 to $20 on Aug. 28, 2024. This analyst has an accuracy rate of 67%.</li>
</ul>
Considering buying JWN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="443" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-1024x443.png" alt="" class="wp-image-807808" style="width:615px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-1024x443.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-300x130.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14-768x332.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04055202/image-14.png 1462w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3"> </a>
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Markets

Trading Ideas

Top Wall Street Forecasters Revamp Nordstrom Price Expectations Ahead Of Q4 Earnings

Barclays analyst Nicholas Campanella maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Equal-Weight and raises the price target from $42 to $47.

Barclays Maintains Equal-Weight on Portland Gen Electric, Raises Price Target to $47

Full year 2025 reported revenues are expected to be $54 million to $56 million, inclusive of approximately $1 million of desktop revenues in the first quarter, prior to divestiture.
Management expects further acceleration above 20% in 2026, driven by three defined catalysts: the need for equipment modernization, the launch of the next-gen MX908 mass spec, and the anticipated full-rate production award for the Department of Defense's AVCAD program.

908 Devices Expects 2025 Revenues From Cont Ops Of $53M - $55M, Representing 11% - 15% YoY Growth; Expects Further Acceleration Above 20% In 2026

Barclays analyst Nicholas Campanella maintains Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) with a Overweight and lowers the price target from $293 to $282.

Barclays Maintains Overweight on Talen Energy, Lowers Price Target to $282

IONQ

IonQ Announced It Has Delivered And Commissioned Quantum Networking System Optimized For Research And Development To The U.S. Air Force Research Laboratory In Rome, New York

Barclays analyst Nicholas Campanella maintains Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) with a Equal-Weight and raises the price target from $10 to $11.

Barclays Maintains Equal-Weight on Hawaiian Electric Indus, Raises Price Target to $11

Evolution Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPM#NYSE">EPM</a>) ("Evolution" or the "Company") today announced that it has entered into a definitive agreement to acquire non-operated oil and natural gas assets in New Mexico, Texas, and Louisiana (the "Acquisition"). The total purchase price for the Acquisition is $9.0 million, subject to customary closing adjustments. The Acquisition is expected to close by the end of Evolution's third quarter of fiscal 2025 with an effective date of February 1, 2025. The Company intends to finance the Acquisition through a combination of cash on hand and borrowings under its existing credit facility.
Kelly Loyd, President and Chief Executive Officer, commented: "This Acquisition marks our 7th such transaction in the last 6 years and is another step forward in strengthening our production base – aligns with our disciplined growth strategy by adding high-quality, low-decline production at an attractive valuation, estimated at ~2.8x NTM2 Adjusted EBITDA1 which doesn't include any incremental cash flows for upside opportunities. These assets complement our existing portfolio and enhance our ability to generate stable free cash flow, which supports our long-standing commitment to returning capital to shareholders. We see additional upside through reactivations of existing waterfloods and through operational efficiencies, which will further enhance long-term value."
The Acquisition expands Evolution's diverse asset portfolio with approximately 440 barrels of oil equivalent per day (BOEPD) of net production, consisting of a balanced commodity mix of 60% oil and 40% natural gas. The acquired assets are primarily low-decline, Proved Developed Producing (PDP) properties, characterized by a sub-7% annual base decline, ensuring stable cash flows and long-term value creation. The transaction is immediately accretive to all key metrics, reinforcing Evolution's ability to sustain and grow its shareholder returns. The portfolio consists of approximately 254 gross producing wells across all regions. The assets will be managed by a top-tier private operator, ensuring operational efficiency and the ability to maximize value.

Evolution Petroleum Acquires $9M Oil and Gas Assets, Expands Production in New Mexico, Texas, and Louisiana

908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) reported quarterly sales of $18.82 million which beat the analyst consensus estimate of $16.39 million by 14.85 percent. This is a 31.14 percent increase over sales of $14.35 million the same period last year.

Earnings Beats

908 Devices Q4 Sales $18.82M Beat $16.39M Estimate

This approval marks a significant milestone in emissions management, empowering operators to integrate AOGI into their emissions monitoring programs to detect and locate fugitive methane emissions with unmatched efficiency and precision.

ChampionX's Aerial Optical Gas Imaging (AOGI) Platform Earns EPA Approval

General

Redwire Bags Study Contract By The European Space Agency (ESA) To Conceptualize A spacecraft Platform For Mars

Barclays analyst Nicholas Campanella maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and raises the price target from $95 to $102.

Barclays Maintains Equal-Weight on Ameren, Raises Price Target to $102

Wellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>, the ", Company", ))), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, is collaborating with Protega Pharmaceuticals Inc. ("Protega"). Protega is the innovative specialty pharmaceutical company that launched ROXYBOND&#x2122; (oxycodone hydrochloride), the first and only FDA-approved abuse-deterrent immediate-release (IR) opioid pain medication in the U.S. The collaboration is meant to support pharmacist education on abuse-deterrent pain management options and regulatory compliance as well as increase patient access to ROXYBOND&#x2122; for appropriately prescribed patients.
Wellgistics LLC is a pharmaceutical wholesaler and National Association of Boards of Pharmacy ("NABP") authorized distributor that serves over 5,400 independent pharmacies across all 50 states. The relationship will support education to these pharmacies and help provide distribution of ROXYBOND&#x2122; to appropriately prescribed patients, particularly in underserved and rural areas where Wellgistics LLC's independent pharmacy clients play a critical role in patient care.

WGRX

Wellgistics Partners with Protega to Expand Access to Abuse-Deterrent Opioid Pain Medication, Support Pharmacist Education, Distribute ROXYBOND to Independent Pharmacies Nationwide

FROG

JFrog Launched Secure AI Model Delivery Accelerated By NVIDIA NIM Microservices

On Tuesday, the Israeli Ministry of Health and the Institutional Review Board (IRB) approved MIRA Pharmaceuticals, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) Phase 1 trial for Ketamir-2, the company's novel oral ketamine analog in development for neuropathic pain.
In December, MIRA Pharmaceuticals submitted an Investigational New Drug (IND) application to the FDA to start <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42576911/exclusive-mira-pharmaceuticals-files-fda-application-to-start-human-trials-for-its-lead-pain-treatment" rel="noreferrer noopener">human trials for Ketamir-2</a>.
MIRA's preclinical studies demonstrate Ketamir-2's superior efficacy, safety, and optimized pharmacokinetics, supporting its advancement into Phase 1 clinical trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42411562/exclusive-mira-pharmaceuticals-validates-ketamir-2s-safety-profile-paving-way-for-human-trials-in-neuropathic-pain" rel="noreferrer noopener">EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain</a>
Subject recruitment is scheduled to begin in the first quarter of 2025.
The study will be conducted at the Clinical Pharmacology Unit, Hadassah Medical Center in Jerusalem, Israel.
The Phase 1, randomized, double-blind, placebo-controlled, single-center study evaluates the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers.
The trial consists of two parts:
<ul>
<li>Single Ascending Dose (SAD) Part: 32 participants</li>
<li>Multiple Ascending Dose (MAD) Part: 24 participants</li>
</ul>
In addition to assessing the frequency and severity of adverse events (AEs) and serious adverse events (SAEs), the study will closely evaluate ketamine-related behavioral side effects and assess Ketamir-2's distinct pharmacological profile.
The decision to conduct the study in Israel was made to accelerate timelines and optimize costs, allowing Mira to efficiently allocate resources and extend its operational runway.
The company expects Phase 1 to conclude by the fourth quarter of 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.
Neuropathic pain is a rapidly growing market, projected to reach $5.2 billion in North America by 2030.
Beyond neuropathic pain, MIRA Pharmaceuticals is conducting ongoing preclinical studies evaluating Ketamir-2 in post-traumatic stress disorder (PTSD) and a potential topical formulation for localized pain relief.
These additional indications could significantly broaden the clinical and commercial potential of Ketamir-2.
In parallel, the company is assessing Mira-55 for its potential in memory enhancement.
Price Action: MIRA stock traded higher by 7.52% to $0.98 premarket at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44103223/broadcom-debuts-velosky-to-accelerate-5g-and-satellite-adoption" target="_blank" rel="noreferrer noopener">Broadcom Debuts VeloSky To Accelerate 5G And Satellite Adoption</a></li>
</ul>

Biotech

Health Care

Market-Moving Exclusives

Exclusives

MIRA

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

Small Cap

Press Releases

ZK International Group Co., Ltd. Announces Record Revenue of $52.89 Million, an Increase of 6.5% for the First Half of Fiscal Year 2024

Micro Cap Outperforms Broader Market Following H1 Revenue Results

Commodities

Contracts

ZK International Group's Breakthrough Win in the Shenzhen Gas Project is Expected to Propel Growth Amid China's Economic Stimulus Which Should Exceed $284 Billion

ZK International Group Seeks to Accept Cryptocurrency Payments to Enhance Global Supplier, Vendor, and Customer Transactions

ZK International Group Announces 405% Gross Profit Increase for the Fiscal Year 2024

ZK International Group Co., Ltd. Announces Shareholder Call to Discuss Upcoming News and Strategic Growth Plans

Stock Split

ZK International Group Announces 1-for-7 Reverse Stock Split

Fintech

ZK International's xSigma Corp. Plans to Launch xSigma Wallet: A Crypto Platform for Buying Memecoins & Digital Assets with Credit Cards

ZK International Postpones Shareholder Call

ZK International Group Co., Ltd. Resolves Nasdaq Bid Price Deficiency and Remains in Compliance with Nasdaq Listing Standards

Comments

ZK International Gr Co

Noticias

Últimas noticias sobre ZK International Gr Co (NASDAQ:ZKIN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL